TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03787563
Drug: Placebo Tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar looking inert placebo tea.
Study: NCT02891616
Drug: 18F-fluorothymidine
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00593099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo capsules (PLA) containing only a dextrose matrix.
Study: NCT00554177
Drug: Medicane (mifepristone)
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 1200mg, Administered 2-3 days apart
Study: NCT00554177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 1200mg, administered 2-3 days apart
Study: NCT03535272
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo manufactured to mimic pepto bismol
Study: NCT03737851
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for infusion
Study: NCT01077154
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously for up to 5 years
Study: NCT04566445
Drug: GT005: Medium Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will test two doses of GT005: Medium Dose and High Dose.
Study: NCT04566445
Drug: GT005: High Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will test two doses of GT005: Medium Dose and High Dose.
Study: NCT03787043
Drug: FDC(MP-513 10mg/Metformin XR 750mg)
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01067547
Drug: Iron Sucrose.
Approvals — FDA: no, EMA: no, PMDA: no
Description: The total dose of iron sucrose given will be individualised by calculating their iron deficit.
Study: NCT01432782
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 4 ml
Study: NCT02653261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An equal volume of saline
Study: NCT04215809
Drug: APG2575
Approvals — FDA: no, EMA: no, PMDA: no
Description: APG2575 investigation drug in ramp up dosing
Study: NCT00859027
Drug: Placebo risedronate oral tablet
Normalized name: risedronate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet by mouth every week as directed
Study: NCT00388674
Drug: Other anti-HBV medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets / Oral Solution, Oral, depends on chosen active comparator, depends on chosen active comparator, Investigator/Patient decision
Study: NCT01635686
Drug: DWP422 25mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01635686
Drug: ENBREL 25MG PFS INJ.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01327183
Drug: RO4905417
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI
Study: NCT01327183
Drug: RO4905417
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI
Study: NCT01327183
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv infusion, completed at least 1 hour and up to 24 hours before PCI
Study: NCT04945629
Drug: Blood clot and simple suture
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filling the alveolus with blood clot
Study: NCT01866995
Drug: Raylis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg)
Study: NCT01744782
Drug: RP103
Normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteamine Bitartrate Delayed-release Capsules (RP103) were administered twice daily, orally or via gastrostomy tube (G-tube), after a 2-hour fast. The starting dose was one-quarter of the RP103 targeted maintenance dose based on age, weight, and body surface area. The recommended targeted maintenance dose for children up to 6 years old was 1 gram/m²/day, in 2 divided doses given Q12H. The dose was gradually escalated, in 10% steps, based on monitoring of WBC cystine levels 30 minutes after the morning RP103 dose collected every 2 weeks, until the participant's WBC cystine level was \<1 nmol ½ cystine/mg protein.
Study: NCT03220022
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03220022
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04531059
Drug: Tetracycline,Metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for H. pylori eradication
Study: NCT04531059
Drug: Minocycline,Metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for H. pylori eradication
Study: NCT03401398
Drug: Hydrocortisone, sodium succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the hydrocortisone treatment arm will receive an initial bolus of 2 mg/kg IV hydrocortisone, followed by 1 mg/kg (maximum 50 mg) of hydrocortisone dosed every six hours for a maximum of seven days or until all vasoactive infusions have been discontinued for at least 12 hours, whichever comes first. When the hydrocortisone course is completed, the medication will be discontinued.
Study: NCT03401398
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the placebo treatment arm will receive an equivalent volume of normal saline, with the identical dosing schedule to the intervention (hydrocortisone) arm.
Study: NCT03785106
Drug: Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
Study: NCT01047969
Drug: Adjuvant Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: If after MRI + FDG-PET 8 weeks post CRT the patient shows no visible tumour or further regression adjuvant chemotherapy will be considered.
Study: NCT01284049
Drug: Intralipid 20%®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Intralipid 20%® at a dose ranging between 0.5 and 1 g/kg/infusion during 12 weeks.
Study: NCT01284049
Drug: OMEGAVEN 10%®
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMEGAVEN 10%® will be used as the sole lipid supplement at a dose of 0.5 to 1.0 g/kg/Infusion with a maximum dose per infusion of 40 grams, in view of formulation constraints during 12 weeks.
Study: NCT02403687
Drug: Diclofenac Sodium 3%
Normalized name: Diclofenac Sodium 3% Topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: compound topical cream
Study: NCT02403687
Drug: Flurbiprofen 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: compound topical cream
Study: NCT00504842
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00438932
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanthanum Carbonate placebo given three times a day with meals.
Study: NCT02403687
Drug: Meloxicam 0.09%
Approvals — FDA: no, EMA: no, PMDA: no
Description: compound topical cream
Study: NCT00008255
Drug: INS316
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00354731
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
Study: NCT01416831
Drug: High-dose IL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 will be given on a Monday at a dose of 600,000 IU per kilogram IV every 8 hours for up to 14 doses each cycle. The second cycle is planned 16 days after cycle 1 but may be delayed up to one week to allow toxicity to resolve. The maximum number of doses that can be given during two cycles will be 28 doses. Patients who respond after two cycles can receive 4 more cycles of IL-2. Patients with disease progression after 2 cycles may elect to receive radiation before a 3rd cycle of IL-2. If patients crossover, IL-2 will be given on the Monday following the last dose of radiation, at a dose of 600,000 IU per kilogram IV every 8 hours for a maximum of 14 doses each cycle. Another cycle is planned 16 days after cycle 3 but may be delayed up to one week to allow toxicity to resolve.
Study: NCT01743768
Drug: SB010
Normalized name: CATH,EXTERN SURESTEP START KIT #MECSB010
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (n=19), receiving the active drug substance.
Study: NCT01743768
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (n=19), receiving placebo.
Study: NCT04682639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive etrasimod matching placebo tablet by mouth, once daily during the 24-week Double-Blind Treatment Period.
Study: NCT02128451
Drug: Meperdine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15ml 0.5% bupivacaine,25 mg of meperdine and 1 ml of clonidine will be injected epidurally in meperdine Group.
Study: NCT02128451
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15ml 0.5% bupivacaine, 25 micrograms of fentanyl and 1 ml of clonidine will be injected epidurally in fentanyl Group
Study: NCT00883740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks
Study: NCT04360135
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive acetaminophen the day before surgery
Study: NCT04360135
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive placebo the day before surgery
Study: NCT01094912
Drug: opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01818414
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg of buccal folic acid, 3 hours prior to planned D\&E
Study: NCT00295308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsules daily
Study: NCT01890109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via subcutaneous injection
Study: NCT01286207
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active standard care
Study: NCT02205047
Drug: 5-fluorouracil or Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01293383
Drug: LEO 90105
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ointment
Study: NCT01383954
Drug: Diclofenac Gel
Normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.
Study: NCT00450177
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group
Study: NCT00566618
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Phase I: First Cohort = 4 mg IV Over 15 min. every 4 Weeks; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I.
Study: NCT02535247
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00133094
Drug: Simvastin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04006691
Drug: UGN-101 instillations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with UGN-101 once weekly for a total of 3-6 times; in a retrograde fashion.
Study: NCT02453867
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids are used continually in the active comparator arm and are stopped at the beginning of the study (month 3 after Transplantation) as an Intervention in the experimental arm
Study: NCT02331069
Drug: Dextrose 5% (D5W)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,1,2, and 3 week injection sessions consisting of injection of 2 ml of D5W into the D-T groove at the point of maximal pain at 1-2 cm depth, followed by subcutaneous injection of D5W at 4 cm intervals along the course of the PACN if tenderness is present.
Study: NCT03999229
Drug: SNO
Normalized name: Sno Pilo
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-nitrosylating agent (SNO) Inhalation
Study: NCT03999229
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline transfusion
Study: NCT01653223
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In short statin group: 20 mg per day, start at 5-7 days before surgery and continue for 7 days.~In long statin group: 20 mg per day, start at 5-7 days before surgery and continue for 6 months.
Study: NCT03406780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00238940
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03869736
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour sessions of inhaled oxygen-air mixture (inspired oxygen concentration \~23-30%) to be administered weekly for 4 weeks.
Study: NCT00361491
Drug: SSR149415
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01791647
Drug: myoinositol 1500 mg
Normalized name: mesoinositol hexanicotinate
DrugBank: Inositol nicotinate (DB08949)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04491955
Drug: MSB0011359C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive M7824 via IV infusion over 1 hour (-10 minutes / +20 minutes, that is, over 50 to 80 minutes) once every 2 weeks. M7824 will be administered as a flat dose of 1,200 mg or 300 mg independent of body weight. M7824 is administered as an intravenous infusion with a mandatory 0.2 micron in-line filter.
Study: NCT01580488
Drug: B LEO 35299 20 mg/g cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily application, 3 weeks
Study: NCT01580488
Drug: F LEO 35299 10 mg/g solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily application, 3 weeks
Study: NCT01079078
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04160676
Drug: Hydrocortisone, Ascorbic acid, Thiamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hydrocortisone, ascorbic acid, and thiamine
Study: NCT04160676
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT03964220
Drug: Inhaled Corticosteroid/Long-acting beta-agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: baseline low dose to medium/high dose, baseline medium dose ICS/LABA to high dose ICS/LABA, additional prescription/refill of high-dose-ICS/LABA following the first prescription of baseline high dose ICS/LABA
Study: NCT01177319
Drug: Glutathione
Normalized name: Glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00814619
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00145652
Drug: Neo-Recormon and Venofer
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01330615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
Study: NCT02478398
Drug: Self-injectable epinephrine
Normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular (IM) injection with suggested doses of 0.15 mg for participants weighing 15-30 kg (33-66 pounds) or 0.3 mg for participants weighing ≥30 kg (≥66 pounds), as needed for severe allergic reactions. Epinephrine was only provided in countries/study sites where it was a regulatory requirement.
Study: NCT04057898
Drug: MN-166
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take MN-166 for 12 months followed by a 6-month open-label extension phase.
Study: NCT04057898
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take matching placebo for 12 months followed by a 6-month open-label extension phase.
Study: NCT03949283
Drug: Standard Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin; Docetaxel; Paclitaxel; Carboplatin; Cisplatin; Gemcitabine; Topotecan; Carboplatin, Gemcitabine; Cisplatin, Gemcitabine; Carboplatin, Liposomal Doxorubicin; Carboplatin, Paclitaxel; Carboplatin, Docetaxel. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab.
Study: NCT06520267
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urine culture and antibiotic sensitivity tests were conducted to assess the bacteriological profile. The patients were then prescribed antibiotics based on susceptibility testing for a duration of 1 week.
Study: NCT03620825
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants take indomethacin in tablet form the evening before and the morning of the visit to induce intestinal permeability
Study: NCT02007187
Drug: Danhong injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower
Study: NCT02007187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
Study: NCT00718081
Drug: Oral sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosage of sufentanil
Study: NCT00718081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dosage of placebo
Study: NCT00014755
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04049669
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each chemo-immunotherapy treatment cycle.
Study: NCT01959230
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic solution to be applied as directed.
Study: NCT03799562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same as pregnenolone (active study medication), except placebo dispensed.
Study: NCT04126681
Drug: Hydroxyurea or Interferon-based therapy
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
Study: NCT00679094
Drug: Bowman-Birk inhibitor concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT02710734
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered Day 1 of each 14 day cycle for 3 cycles
Study: NCT02710734
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered Day 1 of each 14 day cycle for 3 cycles
Study: NCT04221217
Drug: Icosapent
Normalized name: Icosapent
DrugBank: Icosapent (DB00159)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icosapent (MND-2119) capsules.
Study: NCT05498896
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT05498896
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT02797275
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: respiratory inhaler with no medication
Study: NCT04271202
Drug: Emgality 120 MG in 1 ML Prefilled Syringe
Normalized name: Emgality 120 MG in 1 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose of 240 mg followed by 2 interventions (1 month apart) of 120 mg - all given as injectables.
Study: NCT04094688
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04094688
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02651428
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session
Study: NCT04588298
Drug: AZD9833
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9833 tablets will be administered orally.
Study: NCT00639158
Drug: ABT-335
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 mg capsule, daily, 12 weeks
Study: NCT00639158
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule, daily, 12 weeks
Study: NCT01325896
Drug: PEG-Intron sc injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: This program is only open to patients with multiple myeloma who have achieved a complete or partial response after a myelosuppressive chemotherapy regimen followed by autologous stem cell infusion of peripheral blood transplant (PBSCT) as treatment intensification. These patients will be treated with PEG-Intron as maintenance therapy, to be permitted during the same concomitant administration of corticosteroids and / or bisphosphonates.~PEG-Intron: 35 mcg per week by subcutaneous injection to progression or recurrence of the disease, or for 5 years maximum.~Patients were administered PEG-Intron to a uniform dose of 15 mg initial week for 2 weeks. If this dose is tolerated, it would be gradually increased to 25 mg and then to 35 mg every 2 weeks, assuming that there is no toxicity of grade 3 or worse.